Evidence mapPaperPMID 39109082Full record

Observational studyFrontiers in endocrinology2024

A real-world observational study on the effect of Qingre Lishi decoction on glycemic profile using continuous glucose monitoring in obese type 2 diabetes adults.

Bingchen Wei, Tianshu Gao, Mingzhe Li, Xiaojun Tian, Jinxi Wang

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bingchen WeiThe First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Tianshu GaoEndocrinology Department, the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Mingzhe LiInternal Medicine Department, the Third Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Xiaojun TianThe Fourth Encephalopathy Department, Shenyang Second Hospital of Traditional Chinese Medicine, Shenyang, China.
Jinxi WangTeaching Laboratory Center, Liaoning University of Traditional Chinese Medicine, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To observe the clinical efficacy and safety of the Qingre Lishi decoction in treating of newly diagnosed overweight and obese patients with type 2 diabetes mellitus (T2DM) from an evidence-based medical perspective. Methods: 70 cases of overweight and obese patients with newly diagnosed T2DM treated in the outpatient clinic of the Department of Endocrinology of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from December 2021 to November 2022 were selected, of which 35 cases were in the observation group and 35 cases were in the control group. The observation group was treated with the Qingre Lishi decoction add lifestyle intervention, and the control group was treated with lifestyle intervention only. We compared and analyzed the fasting blood glucose (FPG), 2-hour postprandial glucose (2hPG), the occurrence of adverse reactions, and the related indexes provided by wearing the CGM device during the observation period of the patients in the two groups. Results: 53 participants completed the clinical trial. In relation of glycemic control, a decreasing trend has shown in both groups, with the decreases in FPG, 2hPG, eHbA1c, and MG in the observation group being higher than those in the control group ( Conclusion: The Qingre Lishi decoction can effectively improve the hyperglycemic condition of overweight and obese patients with newly diagnosed T2DM. It can reduce blood glucose, alleviate blood glucose fluctuations, reduce the incidence of hypoglycemia, and improve patients' adherence and self-confidence in controlling blood glucose. Clinical Trial Registration: https://itmctr.ccebtcm.org.cn/, identifier ITMCTR2024000006.

Indexed as

Blood GlucoseContinuous Glucose MonitoringDiabetes Mellitus, Type 2Drugs, Chinese HerbalObesityAdultAgedFemaleGlycemic ControlHumansHypoglycemic AgentsMaleMiddle AgedTreatment OutcomeBlood GlucoseDrugs, Chinese HerbalHypoglycemic Agentsblood glucose fluctuationCGMnewly diagnosed type 2 diabetes mellitusQingre Lishi decoctiontype of damp-heat trapped spleen

Identifiers

PMID39109082
PMCPMC11300197

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.